Metastatic Melanoma of the Stomach
Publication date: Available online 12 December 2018Source: Cirugía Española (English Edition)Author(s): Sagrario María Santos-Seoane, Lucía Pérez-Casado, Cristina Helguera-Amezua, Miriam Diez-Fernández
Authors: Kowal J, Markiewicz A, Dębicka-Kumela M, Bogdali A, Jakubowska B, Karska-Basta I, Romanowska-Dixon B Abstract Purpose: To perform a retrospective analysis of factors which might affect the occurrence of a relapse of uveal melanoma after 125I brachytherapy. Material and methods: The analysis concerned 343 patients treated in the years 2001-2012. The effect on local recurrence of such factors as patient's sex, age, tumour size, shape, pigmentation, location, presence of orange pigment or petechiae on tumour surface, retinal detachment, and blood or dispersed pigment in vitreous body were studied. Additi...
Conclusions: CT-based surface mould brachytherapy results in better conformity of superficial lesions on small, irregular surfaces such as the nose and inner canthus than electrons with a slightly higher skin dose. PMID: 31969913 [PubMed]
Over the past several years, a wave of new cancer immunotherapy agents referred to as immune checkpoint inhibitors (ICIs) have transformed the standard of care for patients with cancer. ICIs are most commonly used in advanced cancers with palliative intent and recently as frontline therapy for some cancers. These new agents have been shown to extend overall survival (OS) and progression free survival (PFS) in patients with lung cancer, melanoma, Hodgkin lymphoma, renal cell carcinoma, urothelial carcinoma, Merkel cell carcinoma, head and neck cancer, and more.
Conclusion: Albeit limited in scope, our data suggest that cytotoxic therapy with nab-paclitaxel and bevacizumab appear to favorably alter systemic parameters of immune function of potential benefit in combination T-cell directed immune checkpoint inhibitor therapy.
Publication date: Available online 23 January 2020Source: Journal of Clinical NeuroscienceAuthor(s): Arian Lasocki, Kortnye SmithAbstractImmune checkpoint inhibitors, also known as immunotherapy, have revolutionised the treatment of metastatic melanoma, but are frequently associated with immune-related adverse events (irAEs) affecting a variety of organ systems. Here, we present a case of a patient with metastatic melanoma, being treated with combination ipilimumab-nivolumab, who developed a foot drop. MRI demonstrated enhancement of the nerve roots of the cauda equina. The patient had other irAEs, which warranted cessatio...
ConclusionsPathogenic mutations identified by gene panel sequencing have potential predictive value for targeted therapy of melanoma and are worth further validation in a larger series of cases. The role of some known mutations (e.g.CDK4R24,PTEN c.801 + 1G > A,CTNNB1S45F) as well as variants of unknown significance identified in this study (e.g.MITFR316K,KITG498S) in the generation of resistance to BRAF/MEK inhibitors should be further investigated.
Artificial intelligence (AI) is ramping up how dermatologists diagnose skin conditions, even serious cancers like melanoma.
ConclusionsWe report a laparoscopic trans-peritoneal approach for the safe, reproducible and efficacious repair of incisional inguinal hernias that result from CLND. In our opinion prevention of hernia recurrence can be achieved by a intraperitoneal large mesh fixed at superior and lateral margin borders with permanent fasteners and using cyanoacrylate glue to overlap inferior margin borders in order to prevent vessels and/or nerve injury.
CONCLUSIONS: Patients for whom SLNB was not indicated had no recurrence or metastasis. In cases where SLNB is indicated, the possibility of metastasis and recurrence may be high even if SLNB is negative or LND is performed, so more aggressive treatment and careful follow-up are crucial. PMID: 31964122 [PubMed]
Publication date: Available online 23 January 2020Source: Seminars in Cancer BiologyAuthor(s): Arthur Liu, Michael A. CurranAbstractAdvances in our understanding of tumor immune biology and development of cancer immunotherapies have led to improved outcomes for patients that suffer from aggressive cancers such as metastatic melanoma. Despite these advances, a significant proportion of patients still fail to benefit, and as a result, attention has shifted to understanding how cancer cells escape immune destruction. Of particular interest is the metabolic landscape of the tumor microenvironment, as recent studies have demons...